Primary extranodal lymphoma of the glands. Literature review and options for best practice in 2019.

Détails

ID Serval
serval:BIB_DB917F9DD87C
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Primary extranodal lymphoma of the glands. Literature review and options for best practice in 2019.
Périodique
Critical reviews in oncology/hematology
Auteur(s)
Belkacemi Y., Sio T.T., Colson-Durand L., Onal C., Villà S., Anacak Y., Krengli M., Thariat J., Ugurluer G., Miller R.C., Mirimanoff R.O., Ozsahin M., To N.H.
ISSN
1879-0461 (Electronic)
ISSN-L
1040-8428
Statut éditorial
Publié
Date de publication
03/2019
Peer-reviewed
Oui
Volume
135
Pages
8-19
Langue
anglais
Notes
Publication types: Journal Article ; Practice Guideline ; Review
Publication Status: ppublish
Résumé
Primary extranodal non-Hodgkin's lymphomas (EN-NHL) are a heterogeneous group of malignancies that involve numerous entities with significant difference in terms of tumor site locations, prognostic factors, biology expression, and therapeutic options. In the literature, many EN-NHL types were reported from limited series which only allowed narrow views for elucidating prognostic factors and defining the role of loco-regional therapies in the era of new systemic and biologically targeted therapies. The Rare Cancer Network (RCN), an international multidisciplinary consortium, has published a number of reports on several EN-NHL sites which included many gland locations. In this review, we will focus on the recent literature for a selected number of EN-NHL types in both exocrine and endocrine gland locations. We aim to provide renewed and clear messages for the best practice in 2019 for diagnosis, histopathology, treatments, and also their prognostic implications. We believe that better understanding of molecular and genetic characteristics of these particular diseases is crucial for an appropriate management in the era of personalized treatment developments.
Mots-clé
Adult, Female, Humans, Lymphoma, Non-Hodgkin/diagnosis, Lymphoma, Non-Hodgkin/pathology, Lymphoma, Non-Hodgkin/therapy, Male, Clinical practice, Extranodal non-Hodgkinlymphoma, Glands, Lymphoma, Radiation therapy, Rare cancer, Rituximab
Pubmed
Web of science
Création de la notice
07/04/2019 15:52
Dernière modification de la notice
20/08/2019 16:00
Données d'usage